Drug pipeline: Q111

Drug approvals picked up speed in the US and Europe in Q1. Registrations included Bristol-Myers Squibb's Yervoy (ipilimumab) for melanoma and Human Genome Sciences' Benlysta (belimumab) for lupus. However, MannKind's inhaled insulin (Afrezza), Abbott Laboratories' ABT-874 (briakinumab) and Protalix BioTherapeutics' Uplyso (taliglucerase) suffered setbacks. Efficacy data are in for several new cell and gene therapies and Baxter's vero cell–derived flu vaccine showed promise in a key US phase 3 trial.

US regulatory approvals by drug class

Notable regulatory approvals (Q1 2011)

Notable regulatory setbacks (Q1 2011)

Notable upcoming regulatory decisions (Q2 2011)

Notable trial results (Q1 2011)

Box 1: US regulatory approvals by drug class

Box 2: Notable regulatory approvals (Q1 2011)

Box 3: Notable regulatory setbacks (Q1 2011)

Box 4: Notable upcoming regulatory decisions (Q2 2011)

Box 5: Notable trial results (Q1 2011)